Insider Trading Alert - SNI, ONB And BIIB Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 18, 2014, 135 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $235.22 to $501,676,000.00.

Highlighted Stocks Traded by Insiders:

Scripps Networks Interactive (SNI) - FREE Research Report

Necastro Joseph G who is Chief Fin'l & Admin. Officer at Scripps Networks Interactive sold 11,053 shares at $79.24 on March 18, 2014. Following this transaction, the Chief Fin'l & Admin. Officer owned 18,767 shares meaning that the stake was reduced by 37.07% with the 11,053-share transaction.

The shares most recently traded at $79.48, up $0.24, or 0.3% since the insider transaction. Historical insider transactions for Scripps Networks Interactive go as follows:

  • 4-Week # shares sold: 1.6 million
  • 12-Week # shares sold: 1.6 million
  • 24-Week # shares sold: 1.6 million

The average volume for Scripps Networks Interactive has been 861,200 shares per day over the past 30 days. Scripps Networks Interactive has a market cap of $8.9 billion and is part of the services sector and media industry. Shares are down 7.77% year-to-date as of the close of trading on Tuesday.

Scripps Networks Interactive, Inc. develops lifestyle-oriented content for television and the Internet markets in the United States and internationally. It delivers content that focuses on specifically defined topics of interest for audiences and advertisers. The stock currently has a dividend yield of 1.01%. The company has a P/E ratio of 23.3. Currently there are 5 analysts that rate Scripps Networks Interactive a buy, 1 analyst rates it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SNI - FREE

TheStreet Quant Ratings rates Scripps Networks Interactive as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Scripps Networks Interactive Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Old National Bancorp (ONB) - FREE Research Report

Jones Robert G who is President And Ceo at Old National Bancorp bought 241 shares at $14.60 on March 18, 2014. Following this transaction, the President And Ceo owned 66,628 shares meaning that the stake was reduced by 0.36% with the 241-share transaction.

Kamin John R. who is Chief Information Officer at Old National Bancorp bought 41 shares at $14.40 on March 18, 2014. Following this transaction, the Chief Information Officer owned 5,344 shares meaning that the stake was reduced by 0.77% with the 41-share transaction.

The shares most recently traded at $14.67, up $0.27, or 1.86% since the insider transaction. Historical insider transactions for Old National Bancorp go as follows:

  • 4-Week # shares bought: 210
  • 12-Week # shares bought: 210
  • 24-Week # shares bought: 245

The average volume for Old National Bancorp has been 617,800 shares per day over the past 30 days. Old National Bancorp has a market cap of $1.5 billion and is part of the financial sector and banking industry. Shares are down 3.77% year-to-date as of the close of trading on Tuesday.

Old National Bancorp operates as the holding company for Old National Bank, which provides various financial services to individual and commercial customers in the United States. It operates in three segments: Banking, Insurance, and Wealth Management. The stock currently has a dividend yield of 3.01%. The company has a P/E ratio of 14.6. Currently there is 1 analyst that rates Old National Bancorp a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ONB - FREE

TheStreet Quant Ratings rates Old National Bancorp as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, expanding profit margins, increase in net income, notable return on equity and attractive valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Old National Bancorp Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Biogen Idec (BIIB) - FREE Research Report

Holtzman Steven H who is EVP Corporate Development at Biogen Idec sold 1,221 shares at $334.83 on March 18, 2014. Following this transaction, the EVP Corporate Development owned 8,191 shares meaning that the stake was reduced by 12.97% with the 1,221-share transaction.

The shares most recently traded at $354.61, up $19.78, or 5.58% since the insider transaction. Historical insider transactions for Biogen Idec go as follows:

  • 4-Week # shares sold: 43,713
  • 12-Week # shares sold: 68,151
  • 24-Week # shares sold: 70,829

The average volume for Biogen Idec has been 1.4 million shares per day over the past 30 days. Biogen Idec has a market cap of $81.7 billion and is part of the health care sector and drugs industry. Shares are up 25.89% year-to-date as of the close of trading on Tuesday.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. The company has a P/E ratio of 44.2. Currently there are 14 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIIB - FREE

TheStreet Quant Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Idec Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Comcast Considering All-Cash Bid for Fox as Disney Battle Heads to the Wire

Comcast Considering All-Cash Bid for Fox as Disney Battle Heads to the Wire

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Target's Stock Tanks After Q1 Earnings Miss and Slowing Sales

Target's Stock Tanks After Q1 Earnings Miss and Slowing Sales

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Stocks Move Lower on Trade Fears and 4 Other Stories You Must Know Wednesday

Stocks Move Lower on Trade Fears and 4 Other Stories You Must Know Wednesday